Patents by Inventor Xiaohua Xue

Xiaohua Xue has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS
    Publication number: 20250109137
    Abstract: The present application discloses compounds having the following formula: or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, and R4 are defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.
    Type: Application
    Filed: October 4, 2024
    Publication date: April 3, 2025
    Applicant: Janssen Pharmaceutica NV
    Inventors: Steven D. Goldberg, Douglas C. Behenna, Deane Gordon, Luke E. Hanna, Steven A. Loskot, Stefan McCarver, Steven P. Meduna, Timothy B. Rhorer, Kristen Song, Alexander E. Valdes, Dongpei Wu, Xiaohua Xue
  • Imidazopyridazine IL-17 inhibitor compounds
    Patent number: 12173007
    Abstract: The present application discloses compounds having the following formula: or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, and R4 are defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.
    Type: Grant
    Filed: September 26, 2022
    Date of Patent: December 24, 2024
    Assignee: Janssen Pharmaceutica NV
    Inventors: Steven D. Goldberg, Dougas C. Behenna, Deane Gordon, Luke E. Hanna, Steven A. Loskot, Stefan McCarver, Steven P. Meduna, Timothy B. Rhorer, Kristen Song, Alexander E. Valdes, Xiaohua Xue
  • BENZIMIDAZOLES AS MODULATORS OF IL-17
    Publication number: 20240376085
    Abstract: The present application discloses compounds of Formula (I): (I), or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, and R4 are defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.
    Type: Application
    Filed: September 26, 2022
    Publication date: November 14, 2024
    Applicant: Janssen Pharmaceutica NV
    Inventors: Charlotte Pooley Deckhut, Douglas C. Behenna, Scott Bembenek, Steven D. Goldberg, Paul F. Jackson, John Keith, Steven A. Loskot, Connor Martin, Stefan McCarver, Steven P. Meduna, Timothy B. Rhorer, Amy Y. Shih, Virginia M. Tanis, Craig R. Woods, Xiaohua Xue
  • Imidazopyridazines as modulators of IL-17
    Patent number: 12024524
    Abstract: The present application discloses compounds having the following formula: or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 and R5 are defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.
    Type: Grant
    Filed: April 7, 2023
    Date of Patent: July 2, 2024
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Steven Goldberg, David Kummer, John Keith, Craig Woods, Timothy Rhorer, Virginia M. Tanis, Connor Martin, Steven Meduna, Stefan McCarver, Alexander Valdes, Steven Loskot, Douglas Behenna, Alexander Rovira, Charlotte Deckhut, Xiaohua Xue
  • IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17
    Publication number: 20230357254
    Abstract: The present application discloses compounds having the following formula: or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 and R5 are defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.
    Type: Application
    Filed: April 7, 2023
    Publication date: November 9, 2023
    Inventors: Steven GOLDBERG, David KUMMER, John KEITH, Craig WOODS, Timothy RHORER, Virginia M. TANIS, Connor MARTIN, Steven MEDUNA, Stefan McCARVER, Alexander VALDES, Steven LOSKOT, Douglas BEHENNA, Alexander ROVIRA, Charlotte DECKHUT, Xiaohua XUE
  • IMIDAZOPYRIMIDINES AS MODULATORS OF IL-17
    Publication number: 20230242537
    Abstract: The present application discloses compounds of Formula I or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, and R5 are defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.
    Type: Application
    Filed: April 28, 2021
    Publication date: August 3, 2023
    Inventors: Steven Goldberg, Connor Martin, Timothy B. Rhorer, Virginia M. Tanis, Xiaohua Xue
  • Imidazopyridazines as modulators of IL-17
    Patent number: 11702422
    Abstract: The present application discloses compounds having the following formula: or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 and R5 are defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.
    Type: Grant
    Filed: January 14, 2022
    Date of Patent: July 18, 2023
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Steven Goldberg, Timothy B. Rhorer, Connor Martin, Steven P. Meduna, Stefan McCarver, Alexander Valdes, Douglas Behenna, Xiaohua Xue, John Keith
  • Imidazopyridazines as modulators of IL-17
    Patent number: 11691979
    Abstract: The present application discloses compounds having the following formula: or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 and R5 are defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.
    Type: Grant
    Filed: April 28, 2021
    Date of Patent: July 4, 2023
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Steven Goldberg, Craig Woods, Timothy B. Rhorer, Connor Martin, Steven P. Meduna, Stefan McCarver, Alexander Valdes, Steven Loskot, Douglas Behenna, Alexander Raymond Rovira, Xiaohua Xue
  • METHODS OF IDENTIFYING MODULATORS OF THE IL-17 PATHWAY
    Publication number: 20230167497
    Abstract: Methods of identifying agents that modulate the interleukin-17 (IL-17) pathway are described. Said methods use detecting a level of granulocyte colony-stimulating factor (G-CSF) in a cell supernatant and/or detecting an expression level of one gene or a panel of genes of a cell treated with an agent. Also described are probes capable of detecting a gene or panel of genes and kits for identifying agents that modulate the IL-17 pathway.
    Type: Application
    Filed: April 28, 2021
    Publication date: June 1, 2023
    Inventors: Katherine Y. Blain, Aimee Rose de Leon-Tabaldo, Anne M. Fourie, Steven Goldberg, Xuejun Liu, Rosa Luna-Roman, Michael Angelo Rodriguez, Xiaohua Xue
  • IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS
    Publication number: 20230143050
    Abstract: The present application discloses compounds having the following formula: or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, and R4 are defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.
    Type: Application
    Filed: September 26, 2022
    Publication date: May 11, 2023
    Inventors: Steven D. Goldberg, Dougas C. Behenna, Deane Gordon, Luke E. Hanna, Steven A. Loskot, Stefan McCarver, Steven P. Meduna, Timothy B. Rhorer, Kristen Song, Alexander E. Valdes, Dongpei Wu, Xiaohua Xue
  • IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS
    Publication number: 20230147458
    Abstract: The present application discloses compounds having the following formula: or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, and R4 are defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.
    Type: Application
    Filed: September 26, 2022
    Publication date: May 11, 2023
    Inventors: Steven D. Goldberg, Douglas C. Behenna, Deane Gordon, Luke E. Hanna, Steven A. Loskot, Stefan McCarver, Steven P. Meduna, Brock T. Shireman, Alexander E. Valdes, Jennifer D. Venable, Dongpei Wu, Xiaohua Xue
  • IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17
    Publication number: 20230081548
    Abstract: The present application discloses compounds having the following formula: or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 and R5 are defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.
    Type: Application
    Filed: January 14, 2022
    Publication date: March 16, 2023
    Inventors: Steven GOLDBERG, Craig WOODS, Timothy B. RHORER, Connor MARTIN, Steven P. MEDUNA, Stefan McCARVER, Alexander VALDES, Steven LOSKOT, Douglas BEHENNA, Xiaohua XUE
  • IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17
    Publication number: 20220402922
    Abstract: The present application discloses compounds having the following formula: or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 and R5 are defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.
    Type: Application
    Filed: April 28, 2021
    Publication date: December 22, 2022
    Inventors: Steven GOLDBERG, David KUMMER, John KEITH, Craig WOODS, Timothy RHORER, Virginia M. TANIS, Connor MARTIN, Steven MEDUNA, Stefan McCARVER, Alexander VALDES, Steven LOSKOT, Douglas BEHENNA, Alexander ROVIRA, Charlotte DECKHUT, Xiaohua XUE
  • COMPOSITIONS AND METHODS FOR AN IL-17 TARGET ENGAGEMENT ASSAY WITH LARGE MOLECULE MODULATORS
    Publication number: 20220365100
    Abstract: Methods to measure total IL-17 in a biological sample comprising the IL-17 and a large molecule modulator of IL-17.
    Type: Application
    Filed: September 28, 2020
    Publication date: November 17, 2022
    Inventors: Jonathan M. BLEVITT, Aimee Rose DE LEON-TABALDO, Wai-Ping LEUNG, Xiaohua XUE
  • COMPOSITIONS AND METHODS FOR AN IL-17 TARGET ENGAGEMENT ASSAY WITH SMALL MOLECULE MODULATORS
    Publication number: 20220357341
    Abstract: Methods to measure free IL-17 in a sample comprising IL-17 and a small molecule modulator of IL-17.
    Type: Application
    Filed: September 28, 2020
    Publication date: November 10, 2022
    Inventors: Jonathan M. BLEVITT, Aimee Rose DE LEON-TABALDO, Samuel E. DEPRIMO, Steven GOLDBERG, Wai-Ping LEUNG, Amy STRASNER, Xiaohua XUE
  • PHENYL AND PYRIDINYL SUBSTITUTED IMIDAZOLES AS MODULATORS OF RORgT
    Publication number: 20220281823
    Abstract: The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, Ra, Rb, Q1, and Q2 are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-?-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.
    Type: Application
    Filed: May 5, 2022
    Publication date: September 8, 2022
    Applicant: Janssen Pharmaceutica NV
    Inventors: Steven Goldberg, Connor L. Martin, Elizabeth G. Fennema, David A. Kummer, Rachel T. Nishimura, Virginia M. Tanis, Craig R. Woods, Anne M. Fourie, Xiaohua Xue
  • 6-AMINOPYRIDIN-3-YL THIAZOLES AS MODULATORS OF RORyT
    Publication number: 20210221804
    Abstract: The present invention comprises compounds of Formula I. wherein: A1, A2, A3, A4, A5, R1, and R2 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein the syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.
    Type: Application
    Filed: February 23, 2021
    Publication date: July 22, 2021
    Applicant: Janssen Pharmaceutica NV
    Inventors: Steven Goldberg, Kelly McClure, Virginia M. Tanis, Elizabeth G. Fennema, Alec D. Lebsack, Connor L. Martin, Hariharan Venkatesan, Xiaohua Xue, Craig R. Woods
  • 6-AMINOPYRIDIN-3-YL THIAZOLES AS MODULATORS OF RORyT
    Publication number: 20210198251
    Abstract: The present invention comprises compounds of Formula I. wherein: A1, A2, A3, A4, A5, R1, and R2 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein the syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.
    Type: Application
    Filed: February 23, 2021
    Publication date: July 1, 2021
    Applicant: Janssen Pharmaceutica NV
    Inventors: Steven Goldberg, Kelly McClure, Virginia M. Tanis, Elizabeth G. Fennema, Alec D. Lebsack, Connor L. Martin, Hariharan Venkatesan, Xiaohua Xue, Craig R. Woods
  • 6-AMINOPYRIDIN-3-YL THIAZOLES AS MODULATORS OF RORyT
    Publication number: 20210188836
    Abstract: The present invention comprises compounds of Formula I. wherein: A1, A2, A3, A4, A5, R1, and R2 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein the syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.
    Type: Application
    Filed: February 23, 2021
    Publication date: June 24, 2021
    Applicant: Janssen Pharmaceutica NV
    Inventors: Steven Goldberg, Kelly McClure, Virginia M. Tanis, Elizabeth G. Fennema, Alec D. Lebsack, Connor L. Martin, Hariharan Venkatesan, Xiaohua Xue, Craig R. Woods
  • Pyridinyl pyrazoles as modulators of ROR?T
    Patent number: 11034658
    Abstract: The present invention comprises compounds of Formula I. wherein: R1, R3, R4, R5, R6, and Q are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-?-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.
    Type: Grant
    Filed: June 17, 2019
    Date of Patent: June 15, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Steven Goldberg, Connor L. Martin, Elizabeth G. Fennema, Ronald L. Wolin, Anne M. Fourie, Xiaohua Xue